Fig. 3.

Induced effects of CYP3A4 promoter mediated via PXR by SGD, SY and GC in HepG2 (a) and Caco2 (b). There is a significant increase in positive control RIF group and most prescriptions groups when compared with 0.1% DMSO treatment group (p < 0.05). There is no significant decrease in negative control PCN group when compared to the DMSO group (p > 0.05). VC1: cells were transfected with pcDNA3.1-PXR, PRL-SV40, pGL4.17; VC2: cells were transfected with pcDNA3.1, PRL-SV40, pGL4.17-CYP3A4; other groups: cells were transiently transfected with pcDNA3.1-PXR, PRL-SV40, pGL4.17-CYP3A4. All data were obtained from three independent experiments performed by triplicate and expressed as mean ± S.E.M. Statistical significance was determined by one-way ANOVA with Welch correction, followed by the Games Howell test for pairwise comparisons. One-way ANOVA with Welch’s correction revealed significant differences among the groups (Welch’s p < 0.001). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the DMSO group; ▲p < 0.05 represents GC group compared to SY group with the same concentration